$PBM News
Last published 3w ago
- 3w agoPBMPsyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are MetGlobeNewswireNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that both milestones attached to its backstop subscription
- 1mo agoPBMPsyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine DevelopmentGlobeNewswireHIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive
- 2mo agoPBMPsyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine DevelopmentGlobeNewswireNEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived
- 3mo agoLLYDFTXCMPSHELP+4The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBCEli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- 6mo agoPBMPsyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and ManufacturingGlobeNewswireNEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds
- 6mo agoPBMPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment DisorderGlobeNewswireNEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics,
- 6mo agoPBMPsyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at SourceGlobeNewswireNEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and
- 6mo agoPBMPsyence BioMed Welcomes U.S. Executive Action to Advance Research into IbogaineGlobeNewswireNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine
- 7mo agoPBMPsyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical ActivitiesGlobeNewswireNEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 8mo agoPBMPsyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical TrialGlobeNewswireNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 8mo agoPBMPsyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity InvestmentGlobeNewswireNEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 8mo agoPBMPsyence BioMed Announces Results of Annual and Special Meeting of ShareholdersGlobeNewswireNEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 9mo agoPBMPsyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization PathwayGlobeNewswireNEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 9mo agoPBMPsyence BioMed Announces Settlement of Shareholder LitigationGlobeNewswireNEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct
- 9mo agoPBMPsyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitGlobeNewswireNEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of
- 9mo agoPBMPsyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026GlobeNewswireNEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that it adjourned its annual and special meeting of shareholders (the "Meeting")
- 9mo agoPBMPsyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective DateGlobeNewswireNEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), today announced that it has decided to postpone the previously announced effective date of its
- 10mo agoPBMPsyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitGlobeNewswireNEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of
- 10mo agoPBMPsyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value OpportunityGlobeNewswireNEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 10mo agoPBMPsyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m CashGlobeNewswireNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 10mo agoFOLDKBLBPBMPRPHFrom Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning TapeGlobeNewswireDENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies
- 10mo agoPBMPsyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical TrialGlobeNewswireNEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 11mo agoPBMPsyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity ScienceGlobeNewswireNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 11mo agoPBMPsyence BioMed Announces Groundbreaking Psilocybin Longevity Research ProgramGlobeNewswireFirst publicly listed company to actively investigate psilocybin's potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a
- 11mo agoPBMPsyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic MarketsGlobeNewswireNEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 12mo agoPBMPsyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabsGlobeNewswireNEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental
- 1y agoPBMPsyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative CareGlobeNewswireNEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 1y agoPBMPsyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On InvestmentGlobeNewswireNEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet
- 1y agoPBMPsyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025GlobeNewswireNEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet
- 1y agoPBMCorporate Update, August 2025GlobeNewswireNEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ:PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and
- 1y agoPBMPsyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionGlobeNewswireNEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified
- 1y agoPBMPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesGlobeNewswireTORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is
- 1y agoPBMPSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesGlobeNewswireTORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing
- 1y agoPBMPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory BoardGlobeNewswireNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop
- 1y agoPBMPsyence Biomed Announces Closing of $2.0 Million Private PlacementGlobeNewswireNEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has closed its previously announced private placement for the purchase and
- 1y agoPBMPsyence Biomed Announces $2.0 Million Private PlacementGlobeNewswireNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into definitive agreements for the purchase and sale of an
- 1y agoPBMPsyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsGlobeNewswireNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has
- 1y agoPBMPsyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialGlobeNewswirePatient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to
- 1y agoPBMPsyence Biomed Executes Binding Agreements with Optimi Health Corp.GlobeNewswireNEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has progressed beyond the previously-announced non-binding
- 1y agoPBMPsyence Biomedical Issues Shareholder Update Highlighting Recent ProgressGlobeNewswireIndependent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened balance sheet, with
- 1y agoPBMPsyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications HearingGlobeNewswireNEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on
- 1y agoPBMPsyence Biomedical Announces Effective Date for 1-for-75 Share ConsolidationGlobeNewswireNEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced an effective date for its previously-announced share consolidation. At its Annual
- 1y agoPBMPsyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from NasdaqGlobeNewswireNEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and
- 2y agoPBMPsyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabsGlobeNewswirePsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence Group pursuant
- 2y agoPBMPsyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CareGlobeNewswireEmpax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline
- 2y agoPBMPsyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) DevelopmentGlobeNewswireNEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic
- 2y agoPBMPsyence Biomed Provides Update on Previously Announced Acquisition of ClairvoyantGlobeNewswireNEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its
- 2y agoPBMPsyence Biomed Enters into Agreement to Acquire Stake in PsyLabsGlobeNewswireNEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into a conditional share sale agreement with
- 2y agoPBMPsyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesGlobeNewswireInitiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) through
- 2y agoPBMPsyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from NasdaqGlobeNewswireNEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the "Company") (NASDAQ:PBM) announced that on September 12, 2024, the Company received a staff determination letter (the "Determination Letter")